Alemtuzumab has high antitumour activity but "unacceptably high" toxicity in peripheral T-cell lymphoma (PTL) [non-Hodgkin's lymphoma]

Source: Reactions Weekly, Volume 1, Number 1004, 2004-06-05 , pp. 5-5(1)

Publisher: Adis International

Keywords: Alemtuzumab, therapeutic use; Non-Hodgkin's-lymphoma, treatment

Document Type: Research article

Publication date: 2004-01-01

• In this: publication
• By this: publisher
• In this Subject: Pharmacology

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers